CA
NZ
UK
AU
IND
US
● IceCure Medical fell about 11.5% to close near $3.11, for a marketCapitalizationof roughly $10.6 million, even as first-half 2026Revenuerose 45%.
● Autonomix Medical fell roughly 17% in a recent session, extending a sharp retreat from a spectacular spike earlier in the month.
● Basel Medical dropped weeks after regainingNasdaqbid-price compliance, following the mechanics of a multi-month listing saga.
● Bolt Biotherapeutics fell roughly 13% after second-quarter 2026 results underscored how little cash it has left approaching a pivotal data readout.
● EUDA Health Holdings fell 12.67% on August 12, 2026, closing at $13.30, as excitement around a recently announced stem-cell therapy collaboration continued to fade.
● Alamar Biosciences dropped despiteRevenueof $29.4 million, up 82%, and a 60% grossMarginshowing the NULISA platform is gaining commercial traction.
● Aptevo Therapeutics fell about 15.4% on August 12, 2026, selling off on extraordinarily heavyVolumeafter announcing a roughly $4.5 millionCapitalraise.
Hims & Hers Health (NYSE:HIMS) plans to offer some legally available peptides in 2026, but investors and analysts say sales from that initial offering are unlikely to drive meaningful revenue growth this year. Peptide treatments, built from short chains of amino acids, have become …
GoodRx (NASDAQ:GDRX) shares are declining today, down 4.61% to $3.63, despite a wave of bullish analyst commentary, as investors appear to book profits following the stock's post-earnings rally. TD Cowen, Citigroup, and Wells Fargo all raised price targets this week, citing GoodRx's strong second-quarter …
GRAIL (NASDAQ:GRAL) shares are sliding sharply today, down 7.93% to around $69.50, giving back recent gains despite a broadly supportive healthcare sector trading near 52-week highs. The pullback follows news that the FDA's Molecular and Clinical Genetics Advisory Committee has scheduled a panel to …
Please wait processing your request...